- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07945314
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy Participants
A Phase 1, Randomized, Placebo-Controlled, Investigator- and Participant-Blinded, Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy Participants
The main purpose of this study is to see if LY3839056 is safe and well tolerated when given as a single dose into a vein intravenous (IV) or under the skin subcutaneous (SC) in healthy participants. The study will also measure how much LY3839056 gets into the blood and how long it takes the body to remove it. The study will last up to 17 weeks and includes a stay of about 6 days at the clinical research unit.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: 1-877-CTLILLY (1-877-285-4559) or
- Telefonnummer: 1-317-615-4559
- E-post: LillyTrials@lilly.com
Studiesteder
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200040
- Huashan Hospital, Fudan University (复旦大学附属华山医院) 12 Urumqi Middle Road
-
Ta kontakt med:
- Xiaojie Wu, PhD
- Telefonnummer: 13524686330
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
- Are overtly healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and Cardiac Monitoring.
- Have clinical laboratory test results within normal reference range for the population or the clinical research site, or results with acceptable deviations that are judged to be not clinically significant by the investigator.
- Have venous access sufficient to allow for IV drug delivery and blood sampling as per the protocol.
- Have a body mass index within the range of 18.0 to 32.0 kg/m².
- Participants assigned male or female at birth, including individuals of childbearing potential (IOCBP), may participate in this trial.
- Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
Key Exclusion Criteria:
- Are immunocompromised or have a history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection.
- Have a history or presence of cardiovascular, respiratory, hepatic, ophthalmological, renal, gastrointestinal, endocrine, hematological, neurological, or psychiatric disorders.
- Had any surgical procedure (except for minor surgery requiring local or no anesthesia and without any complications or sequelae) within 12 weeks prior to screening, or any planned surgical procedure scheduled to occur during the study.
- Have a clinically significant history of multiple or severe allergies or an anaphylactic reaction to prescription or nonprescription drugs or food.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Cohort 1 IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Andre navn:
|
|
Eksperimentell: Cohort 2 IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Andre navn:
|
|
Eksperimentell: Cohort 3 IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Andre navn:
|
|
Eksperimentell: Cohort 4a IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Andre navn:
|
|
Eksperimentell: Cohort 4b SC
Participants will receive LY3839056 Subcutaneously |
LY3839056 Administered Subcutaneously
Andre navn:
|
|
Eksperimentell: Cohort 5 IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Andre navn:
|
|
Eksperimentell: Cohort 6a IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Andre navn:
|
|
Eksperimentell: Cohort 6b SC
Participants will receive LY3839056 Subcutaneously |
LY3839056 Administered Subcutaneously
Andre navn:
|
|
Placebo komparator: Placebo IV
Participants will receive Placebo Intravenously |
Placebo Administered Intravenously
Andre navn:
|
|
Placebo komparator: Placebo SC
Participants will receive Placebo Subcutaneously |
Placebo Administered Subcutaneously
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
To evaluate the safety and tolerability of LY3839056 following single-dose administration (IV or SC) in healthy participants.
Tidsramme: Baseline through Day 85
|
Frequency of AEs, TEAEs, SAEs, and Discontinuation due to TEAEs. |
Baseline through Day 85
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
PK: Cmax
Tidsramme: Predose on Day 1 up to Day 85
|
Maximum Observed Concentration (Cmax) of LY3839056 following single SC or IV dose |
Predose on Day 1 up to Day 85
|
|
PK: AUC
Tidsramme: Predose on Day 1 up to Day 85
|
Area Under the Concentration Versus Time Curve (AUC) of LY3839056 following single SC or IV dose |
Predose on Day 1 up to Day 85
|
|
PK: t1/2
Tidsramme: Predose on Day 1 up to Day 85
|
Half Life (t1/2) of LY3839056 following single SC or IV dose |
Predose on Day 1 up to Day 85
|
|
PK: F%
Tidsramme: Predose on Day 1 up to Day 85
|
Bioavailability (F%) of LY3839056 following single SC dose |
Predose on Day 1 up to Day 85
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 27924
- J7H-MC-KAAB (Annen identifikator: Eli Lilly and Company)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .